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HE4, CA-125, and cystic 
ovarian mass
To the editor:	The	recent	publication	on	‘HE4,	CA-125,	and	
cystic	ovarian	mass’	is	very	interesting	[1].	Partheen	et	al.	
[1]	concluded	that	HE4	did	not	outperform	CA-125.	Indeed,	
the	use	of	two	biomarkers	might	be	expected	for	increased	
screening	ability;	however,	the	problem	of	the	cost	should	be	
kept	in	mind.	Incremental	analysis	on	additional	cost	should	
be	done.	Based	on	the	present	report,	the	question	is	whether	
it	should	recommend	screening	for	both	HE4	and	CA-125	in	
the	patient	presenting	with	a	suspicious	mass	at	ovary.	This	
topic	is	the	further	point	for	future	studies	as	indicated	in	
many	recent	studies	[1,2].	Finally,	the	use	of	additional	means,	
such	as	ROMA	algorithm	and	symptom	index,	to	add	more	
value	of	using	HE4	and	CA-125	screening	should	also	be	fur-
ther	assessed	[2,3].
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In reply: We	would	like	to	thank	professor	Wiwanitkit	for	
his	interest	in	our	recent	publication	‘HE4,	CA-125,	and	cystic	
ovarian	mass’.	It	is	important	to	emphasize	that	our	report	
concerns	the	use	of	HE4	and	CA-125	as	a	tool	when	a	pelvic	
mass	or	cyst	already	has	been	found	and	the	question	of	refer-
ral	or	not	to	a	specialized	gynecologic-oncology	surgical	unit	
has	to	be	answered.	In	our	study	the	use	of	Risk	of	Malignancy	
Algorithm	(ROMA)	was	also	evaluated.	Our	study	is	however	
not	focusing	on	screening	of	the	general	population	and	
subsequently	symptom	index	was	not	used.	Nevertheless	we	
agree	that	a	thorough	economical	analyze	of	cost	and	evalua-
tion	of	possible	patient	morbidity	should	be	performed	before	
implementation	into	clinical	practice.
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